New Antihyperglycemic Drugs and Heart Failure: Synopsis of Basic and Clinical Data

BioMed Research International

Volumn 2017, Issue , 2017, Pages

  Von Lewinski, Dirk ^a   Kolesnik, Ewald ^a   Wallner, Markus ^a,b   Resl, Michael ^c   Sourij, Harald ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HYPERGLYCEMIC AGENT; METFORMIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; ROSIGLITAZONE; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; HEART FAILURE; HOSPITALIZATION; HUMAN; NONHUMAN; REVIEW; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); COMPLICATION; HEART INFARCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY;

CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS; MYOCARDIAL INFARCTION; SODIUM-GLUCOSE TRANSPORTER 2; THIAZOLIDINEDIONES;

EID: 85028684244     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2017/1253425     Document Type: Review

References (91)

1. S. E. Nissen and K. Wolski, "Effect of rosiglitazone on the risk ofmyocardial infarction and death fromcardiovascular causes, " The New England Journal ofMedicine, vol. 356, no. 24, pp. 2457-2471, 2007.
2. M. A. Bethel and H. Sourij, "Impact of FDA guidance for developing diabetes drugs on trial design: From policy to practice, " Current Cardiology Reports, vol. 14, no. 1, pp. 59-69, 2012.
3. R. R. Holman, H. Sourij, and R. M. Califf, "Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes, " The Lancet, vol. 383, no. 9933, pp. 2008-2017, 2014.
4. D. D. Schocken, E. J. Benjamin, G. C. Fonarowet al., "Prevention of heart failure: A scientific statement from the American Heart Association Councils on epidemiology and prevention, clinical cardiology, cardiovascular nursing, and high blood pressure research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group, " Circulation, vol. 117, no. 19, pp. 2544-2565, 2008.
5. A. G. Bertoni, W. G. Hundley, M. W. Massing, D. E. Bonds, G. L. Burke, and D. C. Goff Jr., "Heart failure prevalence, incidence, and mortality in the elderly with diabetes, " Diabetes Care, vol. 27, no. 3, pp. 699-703, 2004.
6. K. Iglay, H. Hannachi, P. J. Howie et al., "Prevalence and coprevalence of comorbidities among patientswith type 2 diabetes mellitus, " Current Medical Research and Opinion, vol. 32, no. 7, pp. 1243-1252, 2016.
7. D. S. H. Bell, "Heart failure: The frequent, forgotten, and often fatal complication of diabetes, " Diabetes Care, vol. 26, no. 8, pp. 2433-2441, 2003.
8. W. B. Kannel, M. Hjortland, and W. P. Castelli, "Role of diabetes in congestive heart failure: The Framinghamstudy, " The American Journal of Cardiology, vol. 34, no. 1, pp. 29-34, 1974.
9. S. Rubler, J. Dlugash, Y. Z. Yuceoglu, T. Kumral, A. W. Branwood, and A. Grishman, "New type of cardiomyopathy associated with diabetic glomerulosclerosis, " The American Journal of Cardiology, vol. 30, no. 6, pp. 595-602, 1972.
10. T. J. Regan, M. M. Lyons, S. S. Ahmed et al., "Evidence for cardiomyopathy in familial diabetes mellitus, " Journal ofClinical Investigation, vol. 60, no. 4, pp. 884-899, 1977.
11. A. Goldin, J. A. Beckman, A. M. Schmidt, and M. A. Creager, "Advanced glycation end products: sparking the development of diabetic vascular injury, " Circulation, vol. 114, no. 6, pp. 597-605, 2006.
12. V. W. Fischer, H. B. Barner, and L. S. Larose, "Pathomorphologic aspects of muscular tissue in diabetes mellitus, " Human Pathology, vol. 15, no. 12, pp. 1127-1136, 1984.
13. K. H. VanHoeven andS. M. Factor, "Acomparisonof the pathological spectrum of hypertensive, diabetic, and hypertensivediabetic heart disease, " Circulation, vol. 82, no. 3, pp. 848-855, 1990.
14. S.-I. Nunoda, A. Genda, N. Sugihara, A. Nakayama, S. Mizuno, and R. Takeda, "Quantitative approach to the histopathology of the biopsied right ventricular myocardium in patients with diabetes mellitus, " Heart and Vessels, vol. 1, no. 1, pp. 43-47, 1985.
15. D. D. Belke and W. H. Dillmann, "Altered cardiac calcium handling in diabetes, " Current Hypertension Reports, vol. 6, no. 6, pp. 424-429, 2004.
16. A. P. Waller, A. Kalyanasundaram, S. Hayes, M. Periasamy, and V. A. Lacombe, "Sarcoplasmic reticulum Ca2+ ATPase pump is a major regulator of glucose transport in the healthy and diabetic heart, " Biochimica et Biophysica Acta-Molecular Basis of Disease, vol. 1852, no. 5, pp. 873-881, 2015.
17. J. S. Ingwall and R. G. Weiss, "Is the failing heart energy starvedOnusing chemical energy to support cardiac function, " Circulation Research, vol. 95, no. 2, pp. 135-145, 2004.
18. D. Von Lewinski, S. Bruns, S. Walther, H. Kögler, and B. Pieske, "Insulin causes [Ca2+]idependent and [Ca2+]i-independent positive inotropic effects in failing human myocardium, " Circulation, vol. 111, no. 20, pp. 2588-2595, 2005.
19. D. VonLewinski, R. Gasser, P. P. Rainer et al., "Functional effects of glucose transporters in human ventricular myocardium, " European Journal of Heart Failure, vol. 12, no. 2, pp. 106-113, 2010.
20. D. von Lewinski, P. P. Rainer, R. Gasser et al., "Glucosetransporter-mediated positive inotropic effects in human myocardium of diabetic and nondiabetic patients, " Metabolism: Clinical and Experimental, vol. 59, no. 7, pp. 1020-1028, 2010.
21. H.-P. Hermann, B. Pieske, E. Schwarzmüller, J. Keul, H. Just, and G. Hasenfuss, "Haemodynamic effects of intracoronary pyruvate in patients with congestive heart failure: An open study, " Lancet, vol. 353, no. 9161, pp. 1321-1323, 1999.
22. G. Hasenfuss, L. S. Maier, H.-P. Hermann et al., "Influence of pyruvate on contractile performance and Ca2+ cycling in isolated failing human myocardium, " Circulation, vol. 105, no. 2, pp. 194-199, 2002.
23. A. M. From, C. L. Leibson, F. Bursi et al., "Diabetes in heart failure: prevalence and impact on outcome in the population, " The American Journal of Medicine, vol. 119, no. 7, pp. 591-599, 2006.
24. C. Iribarren, A. J. Karter, A. S. Go et al., "Glycemic control and heart failure among adult patients with diabetes, " Circulation, vol. 103, no. 22, pp. 2668-2673, 2001.
25. B. M. Scirica, E. Braunwald, I. Raz et al., "Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial, " Circulation, vol. 132, no. 15, pp. e121-e122, 2015.
26. G. Savarese, C. D'Amore, M. Federici et al., "Effects of Dipeptidyl Peptidase 4 Inhibitors and Sodium-Glucose Linked coTransporter-2 Inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis, " International Journal of Cardiology, vol. 220, pp. 595-601, 2016.
27. J. Kongwatcharapong, P. Dilokthornsakul, S. Nathisuwan, A. Phrommintikul, and N. Chaiyakunapruk, "Effect of dipeptidyl peptidase-4 inhibitors on heart failure: A meta-analysis of randomized clinical trials, " International Journal of Cardiology, vol. 211, pp. 88-95, 2016.
28. M. Luconi, G. Cantini, A. Ceriello, and E. Mannucci, "Perspectives on cardiovascular effects of incretin-based drugs: From bedside to bench, return trip, " International Journal of Cardiology, vol. 241, pp. 302-310, 2017.
29. W. S. D. Silva Júnior, A. F. D. Godoy-Matos, and L. G. Kraemer-Aguiar, "Dipeptidyl peptidase 4: A new link between diabetes mellitus and atherosclerosis" BioMed Research International, vol. 2015, Article ID 816164, 10 pages, 2015.
30. N.-H. Kim, T. Yu, and D. H. Lee, "The nonglycemic actions of dipeptidyl peptidase-4 inhibitors, " BioMed Research International, vol. 2014, Article ID 368703, 10 pages, 2014.
31. J. Zhong, A. Maiseyeu, S. N. Davis, and S. Rajagopalan, "DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition, " Circulation Research, vol. 116, no. 8, pp. 1491-1504, 2015.
32. P. Balakumar and S. A. Dhanaraj, "Cardiovascular pleiotropic actions of DPP-4 inhibitors: A step at the cutting edge in understanding their additional therapeutic potentials, " Cellular Signalling, vol. 25, no. 9, pp. 1799-1803, 2013.
33. A. Solini, C. Rossi, E. Duranti, S. Taddei, A. Natali, and A. Virdis, "Saxagliptin prevents vascular remodeling and oxidative stress in db/db mice. Role of endothelial nitric oxide synthase uncoupling and cyclooxygenase, " Vascular Pharmacology, vol. 76, pp. 62-71, 2015.
34. A. C. Keller, L. A. Knaub, M. W. Miller, N. Birdsey, D. J. Klemm, and J. E. B. Reusch, "Saxagliptin restores vascular mitochondrial exercise response in the Goto-Kakizaki rat, " Journal of Cardiovascular Pharmacology, vol. 65, no. 2, pp. 137-147, 2014.
35. R. P. Mason, R. F. Jacob, R. Kubant, A. Ciszewski, J. J. Corbalan, and T. Malinski, "Dipeptidyl peptidase-4 inhibition with saxagliptin enhanced nitric oxide release and reduced blood pressure and sICAM-1 levels in hypertensive rats, " Journal of Cardiovascular Pharmacology, vol. 60, no. 5, pp. 467-473, 2012.
36. K. A. Connelly, A. Advani, Y. Zhang et al., "Dipeptidyl peptidase-4 inhibition improves cardiac function in experimental myocardial infarction: role of stromal cell-derived factor-1, " Journal of Diabetes, vol. 8, no. 1, pp. 63-75, 2016.
37. J. A. Hiemstra, D. I. Lee, K. Chakir et al., "Saxagliptin and tadalafil differentially alter cyclic guanosine monophosphate (cGMP) signaling and left ventricular function in aorticbanded mini-swine, " Journal of the AmericanHeart Association, vol. 5, no. 4, Article IDe003277, 2016.
38. L. B. Katsnelson, T. Sulman, O. Solovyova, and V. S. Markhasin, "Role of myocardial viscoelasticity in disturbances of electrical andmechanical activity in calciumoverloaded cardiomyocytes: mathematicalmodeling, " Journal ofTheoretical Biology, vol. 272, pp. 83-95, 2011.
39. S.-T. Tang, H. Su, Q. Zhang et al., "Sitagliptin inhibits endothelin-1 expression in the aortic endothelium of rats with streptozotocin-induced diabetes by suppressing the nuclear factor-B/IB system through the activation of AMP-activated protein kinase, " International Journal ofMolecularMedicine, vol. 37, no. 6, pp. 1558-1566, 2016.
40. K. A. Connelly, Y. Zhang, A. Advani et al., "DPP-4 inhibition attenuates cardiac dysfunction and adverse remodeling following myocardial infarction in rats with experimental diabetes, " CardiovascularTherapeutics, vol. 31, no. 5, pp. 259-267, 2013.
41. T.-M. Lee, W.-T. Chen, and N.-C. Chang, "Sitagliptin decreases ventricular arrhythmias by attenuated glucose-dependent insulinotropic polypeptide (GIP)-dependent resistin signalling in infarcted rats, " Bioscience Reports, vol. 36, no. 2, Article ID e00307, 2016.
42. T.-M. Lee, W.-T. Chen, andN.-C. Chang, "Dipeptidyl peptidase-4 inhibition attenuates arrhythmias via a protein kinase adependent pathway in infarcted hearts, " Circulation Journal, vol. 79, no. 11, pp. 2461-2470, 2015.
43. T.-I. Lee, Y.-H. Kao, Y.-C. Chen, J.-H. Huang, M.-I. Hsu, and Y.-J. Chen, "The dipeptidyl peptidase-4 inhibitor-sitagliptin modulates calcium dysregulation, inflammation, and PPARs in hypertensive cardiomyocytes, " International Journal of Cardiology, vol. 168, no. 6, pp. 5390-5395, 2013.
44. G. Esposito, D. Cappetta, R. Russo et al., "Sitagliptin reduces inflammation, fibrosis and preserves diastolic function in a rat model of heart failure with preserved ejection fraction, " British Journal of Pharmacology, 2017.
45. M. A. Alam, M. R. Hasan Chowdhury, P. Jain, M. A. T. Sagor, and H. M. Reza, "DPP-4 inhibitor sitagliptin prevents inflammation and oxidative stress of heart and kidney in two kidney and one clip (2K1C) rats, " Diabetology and Metabolic Syndrome, vol. 7, no. 1, article no. 95, 2015.
46. N. Hamdani, A.-S. Hervent, L. Vandekerckhove et al., "Left ventricular diastolic dysfunction and myocardial stiffness in diabetic mice is attenuated by inhibition of dipeptidyl peptidase 4, " Cardiovascular Research, vol. 104, no. 3, pp. 423-431, 2014.
47. M. Aoyama, H. Kawase, Y. K. Bando, A. Monji, and T. Murohara, "Dipeptidyl Peptidase 4 Inhibition Alleviates Shortage of Circulating Glucagon-Like Peptide-1 in Heart Failure and Mitigates Myocardial Remodeling and Apoptosis via the Exchange Protein Directly Activated by Cyclic AMP 1/Ras-Related Protein 1 Axis, " Circulation: Heart Failure, vol. 9, no. 1, 2016.
48. K. Akita, K. Isoda, K. Shimada, and H. Daida, "Dipeptidylpeptidase-4 inhibitor, alogliptin, attenuates arterial inflammation and neointimal formation after injury in low-density lipoprotein (LDL) receptor-deficient mice, " Journal of the American Heart Association, vol. 4, no. 3, Article ID e001469, 2015.
49. S. Kato, K. Fukui, H. Kirigaya et al., "Inhibition of DPP-4 by alogliptin improves coronary flow reserve and left ventricular systolic function evaluated by phase contrast cine magnetic resonance imaging in patientswith type 2 diabetes and coronary artery disease, " International Journal of Cardiology, vol. 223, pp. 770-775, 2016.
50. M. Yin, H. H. W. Silljé, M. Meissner, W. H. Van Gilst, and R. A. De Boer, "Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure, " Cardiovascular Diabetology, vol. 10, article no. 85, 2011.
51. K. Chinda, J. Sanit, S. Chattipakorn, and N. Chattipakorn, "Dipeptidyl peptidase-4 inhibitor reduces infarct size and preserves cardiac function via mitochondrial protection in ischaemia-reperfusion rat heart, " Diabetes and Vascular Disease Research, vol. 11, no. 2, pp. 75-83, 2014.
52. T. Miyoshi, K. Nakamura, M. Yoshida et al., "Effect of vildagliptin, a dipeptidyl peptidase 4 inhibitor, on cardiac hypertrophy induced by chronic beta-adrenergic stimulation in rats, " Cardiovascular Diabetology, vol. 13, no. 1, article 43, 2014.
53. M. Ishii, R. Shibata, K. Kondo et al., "Vildagliptin stimulates endothelial cell network formation and ischemia-induced revascularization via an endothelial nitric-oxide synthasedependent mechanism, " Journal of Biological Chemistry, vol. 289, no. 39, pp. 27235-27245, 2014.
54. N. Apaijai, H. Pintana, S. C. Chattipakorn, andN. Chattipakorn, "Effects of vildagliptin versus sitagliptin, on cardiac function, heart rate variability and mitochondrial function in obese insulin-resistant rats, " British Journal of Pharmacology, vol. 169, no. 5, pp. 1048-1057, 2013.
55. A. R. Aroor, J. R. Sowers, S. B. Bender et al., "Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male zucker obese rats, " Endocrinology, vol. 154, no. 7, pp. 2501-2513, 2013.
56. V. Vellecco, E. Mitidieri, A. Gargiulo et al., "Vascular effects of linagliptin in non-obese diabetic mice are glucose-independent and involve positive modulation of the endothelial nitric oxide synthase (eNOS)/caveolin-1 (CAV-1) pathway, " Diabetes, Obesity and Metabolism, vol. 18, no. 12, pp. 1236-1243, 2016.
57. X.-W. Wang, F.-X. Zhang, F. Yang et al., "Effects of linagliptin and liraglutide on glucose-and angiotensin II-induced collagen formation and cytoskeleton degradation in cardiac fibroblasts in vitro, " Acta Pharmacologica Sinica, vol. 37, no. 10, pp. 1349-1358, 2016.
58. M. A. Pfeffer, B. Claggett, R. Diaz et al., "Lixisenatide in patients with type 2 diabetes and acute coronary syndrome, " The New England Journal of Medicine, vol. 373, no. 23, pp. 2247-2257, 2015.
59. S. P. Marso, G. H. Daniels, K. B. Frandsen et al., "Liraglutide and cardiovascular outcomes in type 2 diabetes, " New England Journal of Medicine, vol. 375, no. 4, pp. 311-322, 2016.
60. S. P. Marso, S. C. Bain, A. Consoli et al., "Semaglutide and cardiovascular outcomes in patients with type 2 diabetes, " New England Journal of Medicine, vol. 375, no. 19, pp. 1834-1844, 2016.
61. R. R. Holman, M. A. Bethel, J. George et al., "Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial, " American Heart Journal, vol. 174, pp. 103-110, 2016.
62. S. Mojsov, G. Heinrich, I. B. Wilson, M. Ravazzola, L. Orci, and J. F. Habener, "Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing, " Journal of Biological Chemistry, vol. 261, no. 25, pp. 11880-11889, 1986.
63. T. J. Kieffer, C. H. S. McIntosh, and R. A. Pederson, "Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV, " Endocrinology, vol. 136, no. 8, pp. 3585-3596, 1995.
64. V. Serre, W. Dolci, E. Schaerer et al., "Exendin-(9-39) is an inverse agonist of the murine glucagon-like peptide-1 receptor: Implications for basal intracellular cyclic adenosine 3, 5-monophosphate levels and-cell glucose competence, " Endocrinology, vol. 139, no. 11, pp. 4448-4454, 1998.
65. J. J. Meier, "GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus, " Nature Reviews Endocrinology, vol. 8, no. 12, pp. 728-742, 2012.
66. D. J. Drucker and M. A. Nauck, "The incretin system: glucagonlike peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes, " The Lancet, vol. 368, no. 9548, pp. 1696-1705, 2006.
67. L. A. Nikolaidis, S. Mankad, G. G. Sokos et al., "Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion, " Circulation, vol. 109, no. 8, pp. 962-965, 2004.
68. J. Koska, E. A. Schwartz, M. P. Mullin, D. C. Schwenke, and P. D. Reaven, "Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes, " Diabetes Care, vol. 33, no. 5, pp. 1028-1030, 2010.
69. J. Lonborg, N. Vejlstrup, H. Kelbæk et al., "Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction, " European Heart Journal, vol. 33, no. 12, pp. 1491-1499, 2012.
70. M. Tate, A. Chong, E. Robinson, B. D. Green, and D. J. Grieve, "Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes, " British Journal of Pharmacology, vol. 172, no. 3, pp. 721-736, 2015.
71. M. Kim, M. J. Platt, T. Shibasaki et al., "GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure, " Nature Medicine, vol. 19, no. 5, pp. 567-575, 2013.
72. P. Richards, H. E. Parker, A. E. Adriaenssens et al., "Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model, " Diabetes, vol. 63, no. 4, pp. 1224-1233, 2014.
73. P. Wohlfart, W. Linz, T. Hübschle et al., "Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies, " Journal of Translational Medicine, vol. 11, no. 1, article no. 84, 2013.
74. M. Wallner, E. Kolesnik, K. Ablasser et al., "Exenatide exerts a PKA-dependent positive inotropic effect in human atrial myocardium: GLP-1R mediated effects in humanmyocardium, " Journal of Molecular and Cellular Cardiology, vol. 89, pp. 365-375, 2015.
75. J. L. Bos, "Epac proteins: multi-purpose cAMP targets, " Trends in Biochemical Sciences, vol. 31, no. 12, pp. 680-686, 2006.
76. O. Cazorla, A. Lucas, F. Poirier, A. Lacampagne, and F. Lezoualc'h, "The cAMP binding protein Epac regulates cardiac myofilament function, " National Academy of Sciences of the United States of America, vol. 106, no. 33, pp. 14144-14149, 2009.
77. N. J. Freedman, S. B. Liggett, D. E. Drachman, G. Pei, M. G. Caron, and R. J. Lefkowitz, "Phosphorylation and desensitization of the human 1-adrenergic receptor: Involvement of G protein-coupled receptor kinases and cAMP-dependent protein kinase, " Journal of Biological Chemistry, vol. 270, no. 30, pp. 17953-17961, 1995.
78. D. G. Tilley, A. D. Nguyen, and H. A. Rockman, "Troglitazone stimulates-arrestin-dependent cardiomyocyte contractility via the angiotensin II type 1A receptor, " Biochemical and Biophysical Research Communications, vol. 396, no. 4, pp. 921-926, 2010.
79. D. G. Tilley, "G protein-dependent and G protein-independent signaling pathways and their impact on cardiac function, " Circulation Research, vol. 109, no. 2, pp. 217-230, 2011.
80. S. Mangmool, A. K. Shukla, and H. A. Rockman, "-Arrestindependent activation of Ca2+/calmodulin kinase II after 1-adrenergic receptor stimulation, " Journal of Cell Biology, vol. 189, no. 3, pp. 573-587, 2010.
81. B. Zinman, C. Wanner, J. M. Lachin et al., "Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes, " TheNew England Journal ofMedicine, vol. 373, no. 22, pp. 2117-2128, 2015.
82. B. Neal, V. Perkovic, K. W. Mahaffey et al., "Canagliflozin and cardiovascular and renal events in type 2 diabetes, " NewEngland Journal of Medicine, 2017.
83. N. Sattar, J. McLaren, S. L. Kristensen, D. Preiss, and J. J. McMurray, "SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms" Diabetologia, vol. 59, no. 7, pp. 1333-1339, 2016.
84. E. Ferrannini, M. Mark, and E. Mayoux, "CV protection in the EMPA-REG OUTCOME trial: A thrifty substrate hypothesis, " Diabetes Care, vol. 39, no. 7, pp. 1108-1114, 2016.
85. J. Chen, S. Williams, S. Ho et al., "Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members, " DiabetesTherapy, vol. 1, no. 2, pp. 57-92, 2010.
86. S. A. Hawley, R. J. Ford, B. K. Smith et al., "The Na+/glucose cotransporter inhibitor canagliflozin activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels, " Diabetes, vol. 65, no. 9, pp. 2784-2794, 2016.
87. A. Baartscheer, C. A. Schumacher, R. C. I. Wüst et al., "Empagliflozin decreasesmyocardial cytoplasmic Na+ through inhibition of the cardiacNa+/H+ exchanger in rats and rabbits, " Diabetologia, vol. 60, no. 3, pp. 568-573, 2017.
88. J. Habibi, A. R. Aroor, J. R. Sowers et al., "Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodentmodel of diabetes, " Cardiovascular Diabetology, vol. 16, no. 1, 2017.
89. UK Prospective Diabetes Study (UKPDS) Group, "Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34), " The Lancet, vol. 352, no. 9131, pp. 854-865, 1998.
90. C. Lamanna, M. Monami, N. Marchionni, and E. Mannucci, "Effect of metformin on cardiovascular events and mortality: A meta-analysis of randomized clinical trials, " Diabetes, Obesity& Metabolism, vol. 13, no. 3, pp. 221-228, 2011.
91. P. G. Steg and R. Roussel, "Randomized trials to evaluate cardiovascular safety of antihyperglycemic medications, " Circulation, vol. 134, no. 8, pp. 571-573, 2016.